nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—CSF1R—atherosclerosis	0.3	1	CbGaD
Sorafenib—ABCC4—Rosuvastatin—atherosclerosis	0.0294	0.068	CbGbCtD
Sorafenib—UGT1A1—Ezetimibe—atherosclerosis	0.0287	0.0664	CbGbCtD
Sorafenib—UGT1A1—Simvastatin—atherosclerosis	0.0267	0.0618	CbGbCtD
Sorafenib—UGT1A1—Lovastatin—atherosclerosis	0.0261	0.0604	CbGbCtD
Sorafenib—ABCC2—Ezetimibe—atherosclerosis	0.0175	0.0404	CbGbCtD
Sorafenib—ABCC2—Simvastatin—atherosclerosis	0.0162	0.0376	CbGbCtD
Sorafenib—ABCC2—Lovastatin—atherosclerosis	0.0159	0.0368	CbGbCtD
Sorafenib—ABCC2—Pravastatin—atherosclerosis	0.0159	0.0368	CbGbCtD
Sorafenib—ABCG2—Rosuvastatin—atherosclerosis	0.0158	0.0365	CbGbCtD
Sorafenib—ABCG2—Ezetimibe—atherosclerosis	0.0158	0.0365	CbGbCtD
Sorafenib—ABCG2—Pravastatin—atherosclerosis	0.0144	0.0332	CbGbCtD
Sorafenib—CYP3A7—Simvastatin—atherosclerosis	0.0108	0.0251	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0108	0.0251	CbGbCtD
Sorafenib—CYP3A7—Lovastatin—atherosclerosis	0.0106	0.0246	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0106	0.0246	CbGbCtD
Sorafenib—CYP2B6—Simvastatin—atherosclerosis	0.0103	0.0239	CbGbCtD
Sorafenib—CYP3A5—Rosuvastatin—atherosclerosis	0.00875	0.0202	CbGbCtD
Sorafenib—CYP3A5—Simvastatin—atherosclerosis	0.00813	0.0188	CbGbCtD
Sorafenib—CYP3A5—Pravastatin—atherosclerosis	0.00796	0.0184	CbGbCtD
Sorafenib—CYP3A5—Lovastatin—atherosclerosis	0.00796	0.0184	CbGbCtD
Sorafenib—CYP2C8—Simvastatin—atherosclerosis	0.00782	0.0181	CbGbCtD
Sorafenib—CYP2C8—Pravastatin—atherosclerosis	0.00765	0.0177	CbGbCtD
Sorafenib—CYP2C8—Lovastatin—atherosclerosis	0.00765	0.0177	CbGbCtD
Sorafenib—CYP2C19—Rosuvastatin—atherosclerosis	0.00706	0.0163	CbGbCtD
Sorafenib—CYP2C19—Simvastatin—atherosclerosis	0.00656	0.0152	CbGbCtD
Sorafenib—CYP2C19—Lovastatin—atherosclerosis	0.00642	0.0149	CbGbCtD
Sorafenib—CYP2D6—Niacin—atherosclerosis	0.00631	0.0146	CbGbCtD
Sorafenib—CYP2C9—Rosuvastatin—atherosclerosis	0.00587	0.0136	CbGbCtD
Sorafenib—ABCB1—Ezetimibe—atherosclerosis	0.00569	0.0132	CbGbCtD
Sorafenib—CYP2C9—Simvastatin—atherosclerosis	0.00545	0.0126	CbGbCtD
Sorafenib—CYP2C9—Lovastatin—atherosclerosis	0.00534	0.0124	CbGbCtD
Sorafenib—CYP2C9—Pravastatin—atherosclerosis	0.00534	0.0124	CbGbCtD
Sorafenib—ABCB1—Simvastatin—atherosclerosis	0.00529	0.0123	CbGbCtD
Sorafenib—ABCB1—Pravastatin—atherosclerosis	0.00518	0.012	CbGbCtD
Sorafenib—ABCB1—Lovastatin—atherosclerosis	0.00518	0.012	CbGbCtD
Sorafenib—STK10—renal artery—atherosclerosis	0.00501	0.085	CbGeAlD
Sorafenib—CYP2D6—Simvastatin—atherosclerosis	0.00499	0.0115	CbGbCtD
Sorafenib—CYP2D6—Pravastatin—atherosclerosis	0.00488	0.0113	CbGbCtD
Sorafenib—CYP2D6—Lovastatin—atherosclerosis	0.00488	0.0113	CbGbCtD
Sorafenib—CYP3A4—Rosuvastatin—atherosclerosis	0.00341	0.0079	CbGbCtD
Sorafenib—CYP3A4—Ezetimibe—atherosclerosis	0.00341	0.0079	CbGbCtD
Sorafenib—CYP3A4—Simvastatin—atherosclerosis	0.00317	0.00734	CbGbCtD
Sorafenib—CYP3A4—Lovastatin—atherosclerosis	0.0031	0.00718	CbGbCtD
Sorafenib—CYP3A4—Pravastatin—atherosclerosis	0.0031	0.00718	CbGbCtD
Sorafenib—PDGFRA—penis—atherosclerosis	0.00209	0.0355	CbGeAlD
Sorafenib—FLT1—umbilical vein—atherosclerosis	0.00184	0.0312	CbGeAlD
Sorafenib—KDR—umbilical vein—atherosclerosis	0.00156	0.0264	CbGeAlD
Sorafenib—CDKL3—cardiovascular system—atherosclerosis	0.00147	0.025	CbGeAlD
Sorafenib—KDR—hindlimb—atherosclerosis	0.00142	0.0242	CbGeAlD
Sorafenib—TIE1—endothelium—atherosclerosis	0.00136	0.023	CbGeAlD
Sorafenib—CDKL3—adipose tissue—atherosclerosis	0.0013	0.022	CbGeAlD
Sorafenib—TIE1—blood vessel—atherosclerosis	0.00125	0.0213	CbGeAlD
Sorafenib—KDR—appendage—atherosclerosis	0.00122	0.0207	CbGeAlD
Sorafenib—FLT4—endothelium—atherosclerosis	0.00112	0.019	CbGeAlD
Sorafenib—FLT4—blood vessel—atherosclerosis	0.00103	0.0176	CbGeAlD
Sorafenib—FLT1—artery—atherosclerosis	0.00103	0.0175	CbGeAlD
Sorafenib—KDR—artery—atherosclerosis	0.000873	0.0148	CbGeAlD
Sorafenib—FLT1—endothelium—atherosclerosis	0.000872	0.0148	CbGeAlD
Sorafenib—CDK7—connective tissue—atherosclerosis	0.000812	0.0138	CbGeAlD
Sorafenib—FLT1—blood vessel—atherosclerosis	0.000804	0.0137	CbGeAlD
Sorafenib—KDR—endothelium—atherosclerosis	0.000737	0.0125	CbGeAlD
Sorafenib—HIPK3—connective tissue—atherosclerosis	0.000687	0.0117	CbGeAlD
Sorafenib—KDR—blood vessel—atherosclerosis	0.00068	0.0115	CbGeAlD
Sorafenib—KIT—endothelium—atherosclerosis	0.000653	0.0111	CbGeAlD
Sorafenib—MAPK11—adipose tissue—atherosclerosis	0.000633	0.0108	CbGeAlD
Sorafenib—CDK7—adipose tissue—atherosclerosis	0.000623	0.0106	CbGeAlD
Sorafenib—TAOK2—adipose tissue—atherosclerosis	0.000618	0.0105	CbGeAlD
Sorafenib—ZAK—cardiovascular system—atherosclerosis	0.000611	0.0104	CbGeAlD
Sorafenib—KIT—blood vessel—atherosclerosis	0.000603	0.0102	CbGeAlD
Sorafenib—HIPK3—cardiovascular system—atherosclerosis	0.000598	0.0101	CbGeAlD
Sorafenib—PDGFRB—blood vessel—atherosclerosis	0.000589	0.00999	CbGeAlD
Sorafenib—FLT3—connective tissue—atherosclerosis	0.000584	0.00991	CbGeAlD
Sorafenib—TIE1—cardiovascular system—atherosclerosis	0.000559	0.00948	CbGeAlD
Sorafenib—ZAK—adipose tissue—atherosclerosis	0.000538	0.00914	CbGeAlD
Sorafenib—HIPK3—adipose tissue—atherosclerosis	0.000527	0.00895	CbGeAlD
Sorafenib—FLT3—cardiovascular system—atherosclerosis	0.000508	0.00863	CbGeAlD
Sorafenib—TIE1—adipose tissue—atherosclerosis	0.000493	0.00836	CbGeAlD
Sorafenib—MKNK2—connective tissue—atherosclerosis	0.00048	0.00815	CbGeAlD
Sorafenib—BRAF—adipose tissue—atherosclerosis	0.000472	0.00802	CbGeAlD
Sorafenib—RET—connective tissue—atherosclerosis	0.000468	0.00795	CbGeAlD
Sorafenib—FLT4—cardiovascular system—atherosclerosis	0.000462	0.00783	CbGeAlD
Sorafenib—EPHX2—adipose tissue—atherosclerosis	0.000451	0.00766	CbGeAlD
Sorafenib—CDK7—liver—atherosclerosis	0.000437	0.00742	CbGeAlD
Sorafenib—TAOK2—liver—atherosclerosis	0.000433	0.00736	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—atherosclerosis	0.000418	0.00709	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—atherosclerosis	0.000412	0.007	CbGeAlD
Sorafenib—FLT1—connective tissue—atherosclerosis	0.000412	0.007	CbGeAlD
Sorafenib—RAF1—connective tissue—atherosclerosis	0.00041	0.00696	CbGeAlD
Sorafenib—FLT4—adipose tissue—atherosclerosis	0.000407	0.00691	CbGeAlD
Sorafenib—FGFR1—adipose tissue—atherosclerosis	0.000401	0.00682	CbGeAlD
Sorafenib—PDGFRA—connective tissue—atherosclerosis	0.000386	0.00656	CbGeAlD
Sorafenib—MAP3K7—adipose tissue—atherosclerosis	0.00038	0.00645	CbGeAlD
Sorafenib—ZAK—liver—atherosclerosis	0.000378	0.00641	CbGeAlD
Sorafenib—RALBP1—cardiovascular system—atherosclerosis	0.000377	0.0064	CbGeAlD
Sorafenib—HIPK3—liver—atherosclerosis	0.00037	0.00627	CbGeAlD
Sorafenib—MKNK2—adipose tissue—atherosclerosis	0.000368	0.00625	CbGeAlD
Sorafenib—MKNK1—adipose tissue—atherosclerosis	0.000364	0.00617	CbGeAlD
Sorafenib—FLT1—cardiovascular system—atherosclerosis	0.000359	0.00609	CbGeAlD
Sorafenib—RAF1—cardiovascular system—atherosclerosis	0.000357	0.00606	CbGeAlD
Sorafenib—KDR—connective tissue—atherosclerosis	0.000349	0.00592	CbGeAlD
Sorafenib—TIE1—liver—atherosclerosis	0.000345	0.00586	CbGeAlD
Sorafenib—CSF1R—connective tissue—atherosclerosis	0.00034	0.00578	CbGeAlD
Sorafenib—STK10—cardiovascular system—atherosclerosis	0.00034	0.00577	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—atherosclerosis	0.000336	0.00571	CbGeAlD
Sorafenib—RALBP1—adipose tissue—atherosclerosis	0.000333	0.00565	CbGeAlD
Sorafenib—BRAF—liver—atherosclerosis	0.000331	0.00562	CbGeAlD
Sorafenib—EPHX2—liver—atherosclerosis	0.000316	0.00537	CbGeAlD
Sorafenib—FLT1—adipose tissue—atherosclerosis	0.000316	0.00537	CbGeAlD
Sorafenib—RAF1—adipose tissue—atherosclerosis	0.000315	0.00534	CbGeAlD
Sorafenib—FLT3—liver—atherosclerosis	0.000314	0.00533	CbGeAlD
Sorafenib—EPHB6—adipose tissue—atherosclerosis	0.000313	0.00531	CbGeAlD
Sorafenib—KIT—connective tissue—atherosclerosis	0.000309	0.00524	CbGeAlD
Sorafenib—KDR—cardiovascular system—atherosclerosis	0.000303	0.00515	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—atherosclerosis	0.000303	0.00515	CbGeAlD
Sorafenib—Infestation—Ezetimibe—atherosclerosis	0.000303	0.00306	CcSEcCtD
Sorafenib—Infestation NOS—Ezetimibe—atherosclerosis	0.000303	0.00306	CcSEcCtD
Sorafenib—Neuropathy peripheral—Lovastatin—atherosclerosis	0.000302	0.00306	CcSEcCtD
Sorafenib—PDGFRB—connective tissue—atherosclerosis	0.000302	0.00512	CbGeAlD
Sorafenib—STK10—adipose tissue—atherosclerosis	0.0003	0.00508	CbGeAlD
Sorafenib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000299	0.00302	CcSEcCtD
Sorafenib—Erectile dysfunction—Simvastatin—atherosclerosis	0.000298	0.00302	CcSEcCtD
Sorafenib—Dysphagia—Niacin—atherosclerosis	0.000297	0.00301	CcSEcCtD
Sorafenib—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.000297	0.003	CcSEcCtD
Sorafenib—PDGFRA—adipose tissue—atherosclerosis	0.000297	0.00503	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—atherosclerosis	0.000296	0.00503	CbGeAlD
Sorafenib—Jaundice—Ezetimibe—atherosclerosis	0.000295	0.00299	CcSEcCtD
Sorafenib—Arrhythmia—Rosuvastatin—atherosclerosis	0.000292	0.00296	CcSEcCtD
Sorafenib—UGT1A9—liver—atherosclerosis	0.000289	0.00491	CbGeAlD
Sorafenib—Pancreatitis—Pravastatin—atherosclerosis	0.000287	0.0029	CcSEcCtD
Sorafenib—Mental disorder—Rosuvastatin—atherosclerosis	0.000286	0.0029	CcSEcCtD
Sorafenib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000286	0.0029	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000286	0.0029	CcSEcCtD
Sorafenib—FLT4—liver—atherosclerosis	0.000285	0.00484	CbGeAlD
Sorafenib—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000283	0.00286	CcSEcCtD
Sorafenib—FGFR1—liver—atherosclerosis	0.000282	0.00478	CbGeAlD
Sorafenib—Jaundice—Simvastatin—atherosclerosis	0.000281	0.00285	CcSEcCtD
Sorafenib—Erectile dysfunction—Niacin—atherosclerosis	0.000274	0.00277	CcSEcCtD
Sorafenib—Erectile dysfunction—Pravastatin—atherosclerosis	0.000269	0.00273	CcSEcCtD
Sorafenib—KIT—cardiovascular system—atherosclerosis	0.000269	0.00456	CbGeAlD
Sorafenib—KDR—adipose tissue—atherosclerosis	0.000267	0.00454	CbGeAlD
Sorafenib—MAP2K5—adipose tissue—atherosclerosis	0.000267	0.00454	CbGeAlD
Sorafenib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000267	0.0027	CcSEcCtD
Sorafenib—MAP3K7—liver—atherosclerosis	0.000267	0.00453	CbGeAlD
Sorafenib—Weight decreased—Pravastatin—atherosclerosis	0.000265	0.00268	CcSEcCtD
Sorafenib—PDGFRB—cardiovascular system—atherosclerosis	0.000263	0.00446	CbGeAlD
Sorafenib—Erythema multiforme—Lovastatin—atherosclerosis	0.000262	0.00265	CcSEcCtD
Sorafenib—CSF1R—adipose tissue—atherosclerosis	0.000261	0.00443	CbGeAlD
Sorafenib—Angioedema—Rosuvastatin—atherosclerosis	0.00026	0.00263	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000259	0.00262	CcSEcCtD
Sorafenib—MKNK2—liver—atherosclerosis	0.000258	0.00439	CbGeAlD
Sorafenib—Stomatitis—Niacin—atherosclerosis	0.000258	0.00261	CcSEcCtD
Sorafenib—Jaundice—Niacin—atherosclerosis	0.000258	0.00261	CcSEcCtD
Sorafenib—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000257	0.0026	CcSEcCtD
Sorafenib—Flushing—Lovastatin—atherosclerosis	0.000257	0.0026	CcSEcCtD
Sorafenib—Erythema multiforme—Ezetimibe—atherosclerosis	0.000257	0.0026	CcSEcCtD
Sorafenib—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000256	0.00259	CcSEcCtD
Sorafenib—Myocardial infarction—Pravastatin—atherosclerosis	0.000256	0.00259	CcSEcCtD
Sorafenib—MKNK1—liver—atherosclerosis	0.000255	0.00433	CbGeAlD
Sorafenib—Jaundice—Pravastatin—atherosclerosis	0.000254	0.00257	CcSEcCtD
Sorafenib—Flushing—Ezetimibe—atherosclerosis	0.000252	0.00255	CcSEcCtD
Sorafenib—Cough—Rosuvastatin—atherosclerosis	0.000248	0.00251	CcSEcCtD
Sorafenib—Angiopathy—Ezetimibe—atherosclerosis	0.000246	0.0025	CcSEcCtD
Sorafenib—Immune system disorder—Ezetimibe—atherosclerosis	0.000245	0.00248	CcSEcCtD
Sorafenib—Erythema multiforme—Simvastatin—atherosclerosis	0.000245	0.00248	CcSEcCtD
Sorafenib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000245	0.00248	CcSEcCtD
Sorafenib—Alopecia—Lovastatin—atherosclerosis	0.000245	0.00248	CcSEcCtD
Sorafenib—Arthralgia—Rosuvastatin—atherosclerosis	0.000242	0.00245	CcSEcCtD
Sorafenib—Myalgia—Rosuvastatin—atherosclerosis	0.000242	0.00245	CcSEcCtD
Sorafenib—CYP3A7—liver—atherosclerosis	0.000241	0.00409	CbGeAlD
Sorafenib—Flushing—Simvastatin—atherosclerosis	0.00024	0.00243	CcSEcCtD
Sorafenib—Alopecia—Ezetimibe—atherosclerosis	0.00024	0.00243	CcSEcCtD
Sorafenib—Haemoglobin—Niacin—atherosclerosis	0.000239	0.00242	CcSEcCtD
Sorafenib—Mental disorder—Ezetimibe—atherosclerosis	0.000238	0.00241	CcSEcCtD
Sorafenib—Haemorrhage—Niacin—atherosclerosis	0.000238	0.00241	CcSEcCtD
Sorafenib—KIT—adipose tissue—atherosclerosis	0.000237	0.00402	CbGeAlD
Sorafenib—Erythema—Ezetimibe—atherosclerosis	0.000236	0.00239	CcSEcCtD
Sorafenib—Malnutrition—Ezetimibe—atherosclerosis	0.000236	0.00239	CcSEcCtD
Sorafenib—Dysgeusia—Lovastatin—atherosclerosis	0.000236	0.00239	CcSEcCtD
Sorafenib—RALBP1—liver—atherosclerosis	0.000233	0.00396	CbGeAlD
Sorafenib—Muscle spasms—Lovastatin—atherosclerosis	0.000232	0.00235	CcSEcCtD
Sorafenib—PDGFRB—adipose tissue—atherosclerosis	0.000232	0.00393	CbGeAlD
Sorafenib—Infection—Rosuvastatin—atherosclerosis	0.000231	0.00234	CcSEcCtD
Sorafenib—Alopecia—Simvastatin—atherosclerosis	0.000229	0.00232	CcSEcCtD
Sorafenib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000228	0.00231	CcSEcCtD
Sorafenib—Muscle spasms—Ezetimibe—atherosclerosis	0.000227	0.0023	CcSEcCtD
Sorafenib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000227	0.0023	CcSEcCtD
Sorafenib—Mental disorder—Simvastatin—atherosclerosis	0.000227	0.0023	CcSEcCtD
Sorafenib—Erythema—Simvastatin—atherosclerosis	0.000226	0.00228	CcSEcCtD
Sorafenib—FLT1—liver—atherosclerosis	0.000222	0.00377	CbGeAlD
Sorafenib—Tinnitus—Niacin—atherosclerosis	0.000222	0.00225	CcSEcCtD
Sorafenib—Erythema multiforme—Pravastatin—atherosclerosis	0.000221	0.00224	CcSEcCtD
Sorafenib—Dysgeusia—Simvastatin—atherosclerosis	0.000221	0.00224	CcSEcCtD
Sorafenib—Flushing—Niacin—atherosclerosis	0.000221	0.00224	CcSEcCtD
Sorafenib—RAF1—liver—atherosclerosis	0.000221	0.00375	CbGeAlD
Sorafenib—Angioedema—Lovastatin—atherosclerosis	0.00022	0.00223	CcSEcCtD
Sorafenib—Anaemia—Ezetimibe—atherosclerosis	0.000219	0.00221	CcSEcCtD
Sorafenib—Tinnitus—Pravastatin—atherosclerosis	0.000218	0.00221	CcSEcCtD
Sorafenib—Cardiac disorder—Pravastatin—atherosclerosis	0.000217	0.0022	CcSEcCtD
Sorafenib—Flushing—Pravastatin—atherosclerosis	0.000217	0.0022	CcSEcCtD
Sorafenib—Muscle spasms—Simvastatin—atherosclerosis	0.000217	0.0022	CcSEcCtD
Sorafenib—Angioedema—Ezetimibe—atherosclerosis	0.000216	0.00219	CcSEcCtD
Sorafenib—Angiopathy—Niacin—atherosclerosis	0.000216	0.00218	CcSEcCtD
Sorafenib—Leukopenia—Lovastatin—atherosclerosis	0.000216	0.00218	CcSEcCtD
Sorafenib—Arrhythmia—Niacin—atherosclerosis	0.000212	0.00215	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000212	0.00214	CcSEcCtD
Sorafenib—Alopecia—Niacin—atherosclerosis	0.00021	0.00213	CcSEcCtD
Sorafenib—STK10—liver—atherosclerosis	0.00021	0.00357	CbGeAlD
Sorafenib—Arrhythmia—Pravastatin—atherosclerosis	0.000209	0.00212	CcSEcCtD
Sorafenib—Anaemia—Simvastatin—atherosclerosis	0.000208	0.00211	CcSEcCtD
Sorafenib—PDGFRA—liver—atherosclerosis	0.000208	0.00353	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—atherosclerosis	0.000208	0.00353	CbGeAlD
Sorafenib—Erythema—Niacin—atherosclerosis	0.000207	0.0021	CcSEcCtD
Sorafenib—Malnutrition—Niacin—atherosclerosis	0.000207	0.0021	CcSEcCtD
Sorafenib—Alopecia—Pravastatin—atherosclerosis	0.000207	0.0021	CcSEcCtD
Sorafenib—Cough—Ezetimibe—atherosclerosis	0.000206	0.00209	CcSEcCtD
Sorafenib—Angioedema—Simvastatin—atherosclerosis	0.000206	0.00209	CcSEcCtD
Sorafenib—Arthralgia—Lovastatin—atherosclerosis	0.000205	0.00208	CcSEcCtD
Sorafenib—Myalgia—Lovastatin—atherosclerosis	0.000205	0.00208	CcSEcCtD
Sorafenib—CYP3A7-CYP3A51P—liver—atherosclerosis	0.000205	0.00347	CbGeAlD
Sorafenib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000204	0.00207	CcSEcCtD
Sorafenib—Hypertension—Ezetimibe—atherosclerosis	0.000204	0.00207	CcSEcCtD
Sorafenib—Leukopenia—Simvastatin—atherosclerosis	0.000202	0.00204	CcSEcCtD
Sorafenib—Myalgia—Ezetimibe—atherosclerosis	0.000201	0.00204	CcSEcCtD
Sorafenib—Arthralgia—Ezetimibe—atherosclerosis	0.000201	0.00204	CcSEcCtD
Sorafenib—Dry mouth—Lovastatin—atherosclerosis	0.000201	0.00203	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.0002	0.00202	CcSEcCtD
Sorafenib—Dysgeusia—Pravastatin—atherosclerosis	0.0002	0.00202	CcSEcCtD
Sorafenib—Muscle spasms—Niacin—atherosclerosis	0.000199	0.00202	CcSEcCtD
Sorafenib—Constipation—Rosuvastatin—atherosclerosis	0.000199	0.00201	CcSEcCtD
Sorafenib—Pain—Rosuvastatin—atherosclerosis	0.000199	0.00201	CcSEcCtD
Sorafenib—UGT1A1—liver—atherosclerosis	0.000198	0.00337	CbGeAlD
Sorafenib—Dry mouth—Ezetimibe—atherosclerosis	0.000197	0.00199	CcSEcCtD
Sorafenib—Anaphylactic shock—Lovastatin—atherosclerosis	0.000197	0.00199	CcSEcCtD
Sorafenib—Muscle spasms—Pravastatin—atherosclerosis	0.000196	0.00198	CcSEcCtD
Sorafenib—Infection—Lovastatin—atherosclerosis	0.000195	0.00198	CcSEcCtD
Sorafenib—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000193	0.00195	CcSEcCtD
Sorafenib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000193	0.00195	CcSEcCtD
Sorafenib—Arthralgia—Simvastatin—atherosclerosis	0.000192	0.00194	CcSEcCtD
Sorafenib—Myalgia—Simvastatin—atherosclerosis	0.000192	0.00194	CcSEcCtD
Sorafenib—Infection—Ezetimibe—atherosclerosis	0.000192	0.00194	CcSEcCtD
Sorafenib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00019	0.00192	CcSEcCtD
Sorafenib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000189	0.00192	CcSEcCtD
Sorafenib—Angioedema—Niacin—atherosclerosis	0.000189	0.00192	CcSEcCtD
Sorafenib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000189	0.00191	CcSEcCtD
Sorafenib—Anaemia—Pravastatin—atherosclerosis	0.000188	0.00191	CcSEcCtD
Sorafenib—MAP2K5—liver—atherosclerosis	0.000188	0.00318	CbGeAlD
Sorafenib—KDR—liver—atherosclerosis	0.000188	0.00318	CbGeAlD
Sorafenib—Anorexia—Lovastatin—atherosclerosis	0.000188	0.0019	CcSEcCtD
Sorafenib—Skin disorder—Ezetimibe—atherosclerosis	0.000187	0.0019	CcSEcCtD
Sorafenib—Angioedema—Pravastatin—atherosclerosis	0.000186	0.00189	CcSEcCtD
Sorafenib—Syncope—Niacin—atherosclerosis	0.000186	0.00188	CcSEcCtD
Sorafenib—Leukopenia—Niacin—atherosclerosis	0.000185	0.00188	CcSEcCtD
Sorafenib—Urticaria—Rosuvastatin—atherosclerosis	0.000184	0.00187	CcSEcCtD
Sorafenib—ABCC4—adipose tissue—atherosclerosis	0.000184	0.00313	CbGeAlD
Sorafenib—Anaphylactic shock—Simvastatin—atherosclerosis	0.000184	0.00186	CcSEcCtD
Sorafenib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000184	0.00186	CcSEcCtD
Sorafenib—HTR2B—adipose tissue—atherosclerosis	0.000183	0.00311	CbGeAlD
Sorafenib—CSF1R—liver—atherosclerosis	0.000183	0.00311	CbGeAlD
Sorafenib—Infection—Simvastatin—atherosclerosis	0.000183	0.00185	CcSEcCtD
Sorafenib—Leukopenia—Pravastatin—atherosclerosis	0.000182	0.00185	CcSEcCtD
Sorafenib—Loss of consciousness—Niacin—atherosclerosis	0.000182	0.00184	CcSEcCtD
Sorafenib—Cough—Niacin—atherosclerosis	0.000181	0.00183	CcSEcCtD
Sorafenib—Thrombocytopenia—Simvastatin—atherosclerosis	0.00018	0.00182	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000179	0.00182	CcSEcCtD
Sorafenib—Cough—Pravastatin—atherosclerosis	0.000178	0.0018	CcSEcCtD
Sorafenib—Myalgia—Niacin—atherosclerosis	0.000176	0.00178	CcSEcCtD
Sorafenib—Arthralgia—Niacin—atherosclerosis	0.000176	0.00178	CcSEcCtD
Sorafenib—Hypertension—Pravastatin—atherosclerosis	0.000176	0.00178	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000176	0.00178	CcSEcCtD
Sorafenib—Anorexia—Simvastatin—atherosclerosis	0.000175	0.00178	CcSEcCtD
Sorafenib—Dyspnoea—Lovastatin—atherosclerosis	0.000175	0.00178	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000175	0.00177	CcSEcCtD
Sorafenib—Arthralgia—Pravastatin—atherosclerosis	0.000174	0.00176	CcSEcCtD
Sorafenib—Myalgia—Pravastatin—atherosclerosis	0.000174	0.00176	CcSEcCtD
Sorafenib—Dyspepsia—Lovastatin—atherosclerosis	0.000173	0.00175	CcSEcCtD
Sorafenib—Dry mouth—Niacin—atherosclerosis	0.000172	0.00175	CcSEcCtD
Sorafenib—Dyspnoea—Ezetimibe—atherosclerosis	0.000172	0.00174	CcSEcCtD
Sorafenib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000171	0.00173	CcSEcCtD
Sorafenib—Decreased appetite—Lovastatin—atherosclerosis	0.000171	0.00173	CcSEcCtD
Sorafenib—Dyspepsia—Ezetimibe—atherosclerosis	0.00017	0.00172	CcSEcCtD
Sorafenib—Fatigue—Lovastatin—atherosclerosis	0.00017	0.00172	CcSEcCtD
Sorafenib—Anaphylactic shock—Niacin—atherosclerosis	0.000169	0.00171	CcSEcCtD
Sorafenib—Constipation—Lovastatin—atherosclerosis	0.000168	0.0017	CcSEcCtD
Sorafenib—Pain—Lovastatin—atherosclerosis	0.000168	0.0017	CcSEcCtD
Sorafenib—Decreased appetite—Ezetimibe—atherosclerosis	0.000168	0.0017	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000168	0.0017	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000167	0.00169	CcSEcCtD
Sorafenib—Asthenia—Rosuvastatin—atherosclerosis	0.000167	0.00169	CcSEcCtD
Sorafenib—Anaphylactic shock—Pravastatin—atherosclerosis	0.000166	0.00168	CcSEcCtD
Sorafenib—Fatigue—Ezetimibe—atherosclerosis	0.000166	0.00168	CcSEcCtD
Sorafenib—Shock—Niacin—atherosclerosis	0.000166	0.00168	CcSEcCtD
Sorafenib—KIT—liver—atherosclerosis	0.000166	0.00282	CbGeAlD
Sorafenib—Infection—Pravastatin—atherosclerosis	0.000165	0.00167	CcSEcCtD
Sorafenib—Pain—Ezetimibe—atherosclerosis	0.000165	0.00167	CcSEcCtD
Sorafenib—Constipation—Ezetimibe—atherosclerosis	0.000165	0.00167	CcSEcCtD
Sorafenib—Pruritus—Rosuvastatin—atherosclerosis	0.000164	0.00166	CcSEcCtD
Sorafenib—Skin disorder—Niacin—atherosclerosis	0.000164	0.00166	CcSEcCtD
Sorafenib—Dyspnoea—Simvastatin—atherosclerosis	0.000164	0.00166	CcSEcCtD
Sorafenib—ABCB1—blood vessel—atherosclerosis	0.000163	0.00277	CbGeAlD
Sorafenib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000163	0.00165	CcSEcCtD
Sorafenib—PDGFRB—liver—atherosclerosis	0.000162	0.00276	CbGeAlD
Sorafenib—Dyspepsia—Simvastatin—atherosclerosis	0.000162	0.00164	CcSEcCtD
Sorafenib—Anorexia—Niacin—atherosclerosis	0.000161	0.00163	CcSEcCtD
Sorafenib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000161	0.00163	CcSEcCtD
Sorafenib—Decreased appetite—Simvastatin—atherosclerosis	0.00016	0.00162	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000159	0.00161	CcSEcCtD
Sorafenib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000159	0.00161	CcSEcCtD
Sorafenib—Fatigue—Simvastatin—atherosclerosis	0.000159	0.00161	CcSEcCtD
Sorafenib—Anorexia—Pravastatin—atherosclerosis	0.000159	0.00161	CcSEcCtD
Sorafenib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000158	0.0016	CcSEcCtD
Sorafenib—Constipation—Simvastatin—atherosclerosis	0.000157	0.00159	CcSEcCtD
Sorafenib—Pain—Simvastatin—atherosclerosis	0.000157	0.00159	CcSEcCtD
Sorafenib—Urticaria—Lovastatin—atherosclerosis	0.000156	0.00158	CcSEcCtD
Sorafenib—Body temperature increased—Lovastatin—atherosclerosis	0.000156	0.00157	CcSEcCtD
Sorafenib—Abdominal pain—Lovastatin—atherosclerosis	0.000156	0.00157	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000154	0.00156	CcSEcCtD
Sorafenib—Dizziness—Rosuvastatin—atherosclerosis	0.000154	0.00155	CcSEcCtD
Sorafenib—Urticaria—Ezetimibe—atherosclerosis	0.000153	0.00155	CcSEcCtD
Sorafenib—Abdominal pain—Ezetimibe—atherosclerosis	0.000153	0.00154	CcSEcCtD
Sorafenib—Body temperature increased—Ezetimibe—atherosclerosis	0.000153	0.00154	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000152	0.00153	CcSEcCtD
Sorafenib—Dyspnoea—Niacin—atherosclerosis	0.000151	0.00153	CcSEcCtD
Sorafenib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00015	0.00152	CcSEcCtD
Sorafenib—Dyspepsia—Niacin—atherosclerosis	0.000149	0.00151	CcSEcCtD
Sorafenib—Dyspnoea—Pravastatin—atherosclerosis	0.000148	0.0015	CcSEcCtD
Sorafenib—Decreased appetite—Niacin—atherosclerosis	0.000147	0.00149	CcSEcCtD
Sorafenib—Dyspepsia—Pravastatin—atherosclerosis	0.000146	0.00148	CcSEcCtD
Sorafenib—Rash—Rosuvastatin—atherosclerosis	0.000146	0.00148	CcSEcCtD
Sorafenib—Dermatitis—Rosuvastatin—atherosclerosis	0.000146	0.00148	CcSEcCtD
Sorafenib—Urticaria—Simvastatin—atherosclerosis	0.000146	0.00148	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000146	0.00148	CcSEcCtD
Sorafenib—Body temperature increased—Simvastatin—atherosclerosis	0.000145	0.00147	CcSEcCtD
Sorafenib—Abdominal pain—Simvastatin—atherosclerosis	0.000145	0.00147	CcSEcCtD
Sorafenib—Headache—Rosuvastatin—atherosclerosis	0.000145	0.00147	CcSEcCtD
Sorafenib—Hypersensitivity—Lovastatin—atherosclerosis	0.000145	0.00147	CcSEcCtD
Sorafenib—Decreased appetite—Pravastatin—atherosclerosis	0.000145	0.00146	CcSEcCtD
Sorafenib—Pain—Niacin—atherosclerosis	0.000145	0.00146	CcSEcCtD
Sorafenib—Fatigue—Pravastatin—atherosclerosis	0.000143	0.00145	CcSEcCtD
Sorafenib—Constipation—Pravastatin—atherosclerosis	0.000142	0.00144	CcSEcCtD
Sorafenib—Pain—Pravastatin—atherosclerosis	0.000142	0.00144	CcSEcCtD
Sorafenib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000142	0.00144	CcSEcCtD
Sorafenib—Asthenia—Lovastatin—atherosclerosis	0.000141	0.00143	CcSEcCtD
Sorafenib—Pruritus—Lovastatin—atherosclerosis	0.000139	0.00141	CcSEcCtD
Sorafenib—Asthenia—Ezetimibe—atherosclerosis	0.000138	0.0014	CcSEcCtD
Sorafenib—Gastrointestinal pain—Niacin—atherosclerosis	0.000138	0.0014	CcSEcCtD
Sorafenib—Nausea—Rosuvastatin—atherosclerosis	0.000138	0.0014	CcSEcCtD
Sorafenib—Pruritus—Ezetimibe—atherosclerosis	0.000137	0.00138	CcSEcCtD
Sorafenib—CYP2B6—cardiovascular system—atherosclerosis	0.000136	0.00231	CbGeAlD
Sorafenib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000136	0.00138	CcSEcCtD
Sorafenib—Hypersensitivity—Simvastatin—atherosclerosis	0.000136	0.00137	CcSEcCtD
Sorafenib—CYP2C9—cardiovascular system—atherosclerosis	0.000135	0.00229	CbGeAlD
Sorafenib—Diarrhoea—Lovastatin—atherosclerosis	0.000135	0.00136	CcSEcCtD
Sorafenib—Urticaria—Niacin—atherosclerosis	0.000134	0.00136	CcSEcCtD
Sorafenib—Body temperature increased—Niacin—atherosclerosis	0.000134	0.00135	CcSEcCtD
Sorafenib—Abdominal pain—Niacin—atherosclerosis	0.000134	0.00135	CcSEcCtD
Sorafenib—Urticaria—Pravastatin—atherosclerosis	0.000132	0.00134	CcSEcCtD
Sorafenib—Asthenia—Simvastatin—atherosclerosis	0.000132	0.00134	CcSEcCtD
Sorafenib—Diarrhoea—Ezetimibe—atherosclerosis	0.000132	0.00134	CcSEcCtD
Sorafenib—Abdominal pain—Pravastatin—atherosclerosis	0.000132	0.00133	CcSEcCtD
Sorafenib—Body temperature increased—Pravastatin—atherosclerosis	0.000132	0.00133	CcSEcCtD
Sorafenib—Pruritus—Simvastatin—atherosclerosis	0.00013	0.00132	CcSEcCtD
Sorafenib—ABCG2—adipose tissue—atherosclerosis	0.00013	0.00221	CbGeAlD
Sorafenib—Dizziness—Lovastatin—atherosclerosis	0.00013	0.00132	CcSEcCtD
Sorafenib—ABCC4—liver—atherosclerosis	0.000129	0.00219	CbGeAlD
Sorafenib—Dizziness—Ezetimibe—atherosclerosis	0.000128	0.00129	CcSEcCtD
Sorafenib—Diarrhoea—Simvastatin—atherosclerosis	0.000126	0.00127	CcSEcCtD
Sorafenib—ABCC2—liver—atherosclerosis	0.000125	0.00212	CbGeAlD
Sorafenib—Vomiting—Lovastatin—atherosclerosis	0.000125	0.00127	CcSEcCtD
Sorafenib—Hypersensitivity—Niacin—atherosclerosis	0.000125	0.00126	CcSEcCtD
Sorafenib—Rash—Lovastatin—atherosclerosis	0.000124	0.00126	CcSEcCtD
Sorafenib—Dermatitis—Lovastatin—atherosclerosis	0.000124	0.00125	CcSEcCtD
Sorafenib—Headache—Lovastatin—atherosclerosis	0.000123	0.00125	CcSEcCtD
Sorafenib—Vomiting—Ezetimibe—atherosclerosis	0.000123	0.00124	CcSEcCtD
Sorafenib—Hypersensitivity—Pravastatin—atherosclerosis	0.000123	0.00124	CcSEcCtD
Sorafenib—Dizziness—Simvastatin—atherosclerosis	0.000122	0.00123	CcSEcCtD
Sorafenib—Rash—Ezetimibe—atherosclerosis	0.000122	0.00123	CcSEcCtD
Sorafenib—Dermatitis—Ezetimibe—atherosclerosis	0.000122	0.00123	CcSEcCtD
Sorafenib—Asthenia—Niacin—atherosclerosis	0.000121	0.00123	CcSEcCtD
Sorafenib—Headache—Ezetimibe—atherosclerosis	0.000121	0.00122	CcSEcCtD
Sorafenib—CYP3A5—adipose tissue—atherosclerosis	0.000121	0.00205	CbGeAlD
Sorafenib—Pruritus—Niacin—atherosclerosis	0.00012	0.00121	CcSEcCtD
Sorafenib—Asthenia—Pravastatin—atherosclerosis	0.000119	0.00121	CcSEcCtD
Sorafenib—Pruritus—Pravastatin—atherosclerosis	0.000118	0.00119	CcSEcCtD
Sorafenib—Vomiting—Simvastatin—atherosclerosis	0.000117	0.00118	CcSEcCtD
Sorafenib—Nausea—Lovastatin—atherosclerosis	0.000117	0.00118	CcSEcCtD
Sorafenib—Rash—Simvastatin—atherosclerosis	0.000116	0.00117	CcSEcCtD
Sorafenib—Dermatitis—Simvastatin—atherosclerosis	0.000116	0.00117	CcSEcCtD
Sorafenib—Diarrhoea—Niacin—atherosclerosis	0.000116	0.00117	CcSEcCtD
Sorafenib—Headache—Simvastatin—atherosclerosis	0.000115	0.00117	CcSEcCtD
Sorafenib—Nausea—Ezetimibe—atherosclerosis	0.000115	0.00116	CcSEcCtD
Sorafenib—Diarrhoea—Pravastatin—atherosclerosis	0.000114	0.00115	CcSEcCtD
Sorafenib—Dizziness—Niacin—atherosclerosis	0.000112	0.00113	CcSEcCtD
Sorafenib—Dizziness—Pravastatin—atherosclerosis	0.00011	0.00111	CcSEcCtD
Sorafenib—Nausea—Simvastatin—atherosclerosis	0.000109	0.00111	CcSEcCtD
Sorafenib—CYP2C19—liver—atherosclerosis	0.000108	0.00183	CbGeAlD
Sorafenib—Vomiting—Niacin—atherosclerosis	0.000107	0.00109	CcSEcCtD
Sorafenib—Rash—Niacin—atherosclerosis	0.000107	0.00108	CcSEcCtD
Sorafenib—Dermatitis—Niacin—atherosclerosis	0.000106	0.00108	CcSEcCtD
Sorafenib—Headache—Niacin—atherosclerosis	0.000106	0.00107	CcSEcCtD
Sorafenib—Vomiting—Pravastatin—atherosclerosis	0.000106	0.00107	CcSEcCtD
Sorafenib—Rash—Pravastatin—atherosclerosis	0.000105	0.00106	CcSEcCtD
Sorafenib—Dermatitis—Pravastatin—atherosclerosis	0.000105	0.00106	CcSEcCtD
Sorafenib—Headache—Pravastatin—atherosclerosis	0.000104	0.00106	CcSEcCtD
Sorafenib—Nausea—Niacin—atherosclerosis	0.0001	0.00102	CcSEcCtD
Sorafenib—Nausea—Pravastatin—atherosclerosis	9.88e-05	0.001	CcSEcCtD
Sorafenib—CYP2C8—liver—atherosclerosis	9.39e-05	0.00159	CbGeAlD
Sorafenib—ABCG2—liver—atherosclerosis	9.13e-05	0.00155	CbGeAlD
Sorafenib—CYP1A2—liver—atherosclerosis	8.78e-05	0.00149	CbGeAlD
Sorafenib—CYP3A5—liver—atherosclerosis	8.47e-05	0.00144	CbGeAlD
Sorafenib—CYP2B6—liver—atherosclerosis	8.42e-05	0.00143	CbGeAlD
Sorafenib—CYP2C9—liver—atherosclerosis	8.34e-05	0.00142	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—atherosclerosis	7.28e-05	0.00124	CbGeAlD
Sorafenib—ABCB1—adipose tissue—atherosclerosis	6.42e-05	0.00109	CbGeAlD
Sorafenib—CYP3A4—liver—atherosclerosis	6.36e-05	0.00108	CbGeAlD
Sorafenib—CYP2D6—liver—atherosclerosis	6.26e-05	0.00106	CbGeAlD
Sorafenib—ABCB1—liver—atherosclerosis	4.5e-05	0.000764	CbGeAlD
Sorafenib—CYP3A7—Metabolism—PTGS2—atherosclerosis	1.33e-06	1.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—atherosclerosis	1.33e-06	1.2e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOB—atherosclerosis	1.33e-06	1.2e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STAT3—atherosclerosis	1.32e-06	1.19e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STAT3—atherosclerosis	1.32e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTM1—atherosclerosis	1.32e-06	1.19e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—atherosclerosis	1.32e-06	1.19e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—atherosclerosis	1.32e-06	1.19e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—atherosclerosis	1.32e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—atherosclerosis	1.31e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.3e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.3e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CG—atherosclerosis	1.3e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—LPL—atherosclerosis	1.3e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HMOX1—atherosclerosis	1.29e-06	1.17e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	1.29e-06	1.17e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTM1—atherosclerosis	1.29e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCA1—atherosclerosis	1.29e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.29e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARA—atherosclerosis	1.28e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LIPC—atherosclerosis	1.28e-06	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	1.27e-06	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—atherosclerosis	1.27e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOC3—atherosclerosis	1.27e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CG—atherosclerosis	1.27e-06	1.15e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—atherosclerosis	1.27e-06	1.15e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—atherosclerosis	1.27e-06	1.14e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—LPL—atherosclerosis	1.27e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GPX1—atherosclerosis	1.27e-06	1.14e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—atherosclerosis	1.26e-06	1.14e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK3—atherosclerosis	1.26e-06	1.14e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK3—atherosclerosis	1.26e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LDLR—atherosclerosis	1.26e-06	1.14e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—atherosclerosis	1.26e-06	1.13e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKB1—atherosclerosis	1.26e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—atherosclerosis	1.25e-06	1.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—atherosclerosis	1.25e-06	1.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—atherosclerosis	1.25e-06	1.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—atherosclerosis	1.25e-06	1.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—atherosclerosis	1.25e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOB—atherosclerosis	1.25e-06	1.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—atherosclerosis	1.25e-06	1.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—atherosclerosis	1.25e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AGT—atherosclerosis	1.24e-06	1.12e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOB—atherosclerosis	1.24e-06	1.12e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GPX1—atherosclerosis	1.23e-06	1.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK8—atherosclerosis	1.23e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CETP—atherosclerosis	1.23e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CD36—atherosclerosis	1.23e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INS—atherosclerosis	1.23e-06	1.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—atherosclerosis	1.23e-06	1.11e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—atherosclerosis	1.23e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—atherosclerosis	1.22e-06	1.11e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—atherosclerosis	1.22e-06	1.1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—atherosclerosis	1.22e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—atherosclerosis	1.22e-06	1.1e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—atherosclerosis	1.22e-06	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—atherosclerosis	1.22e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.22e-06	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—atherosclerosis	1.21e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAV1—atherosclerosis	1.21e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—atherosclerosis	1.2e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOA1—atherosclerosis	1.2e-06	1.09e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CD36—atherosclerosis	1.2e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INS—atherosclerosis	1.2e-06	1.08e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK3—atherosclerosis	1.2e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	1.2e-06	1.08e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK3—atherosclerosis	1.2e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—LPL—atherosclerosis	1.19e-06	1.08e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—atherosclerosis	1.19e-06	1.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—atherosclerosis	1.19e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—LPL—atherosclerosis	1.18e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.18e-06	1.07e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	1.18e-06	1.06e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	1.17e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—atherosclerosis	1.17e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GPX1—atherosclerosis	1.16e-06	1.05e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—atherosclerosis	1.16e-06	1.05e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—atherosclerosis	1.16e-06	1.05e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—atherosclerosis	1.16e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—atherosclerosis	1.15e-06	1.04e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—atherosclerosis	1.15e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARA—atherosclerosis	1.15e-06	1.03e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—atherosclerosis	1.14e-06	1.03e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—atherosclerosis	1.14e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CD36—atherosclerosis	1.13e-06	1.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—atherosclerosis	1.13e-06	1.02e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—atherosclerosis	1.13e-06	1.02e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—atherosclerosis	1.13e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—atherosclerosis	1.13e-06	1.02e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—atherosclerosis	1.13e-06	1.02e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—atherosclerosis	1.12e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CD36—atherosclerosis	1.12e-06	1.01e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKB1—atherosclerosis	1.12e-06	1.01e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARA—atherosclerosis	1.12e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.12e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGT—atherosclerosis	1.11e-06	1e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.1e-06	9.98e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—atherosclerosis	1.1e-06	9.94e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK8—atherosclerosis	1.1e-06	9.93e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—atherosclerosis	1.1e-06	9.93e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—atherosclerosis	1.1e-06	9.92e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—atherosclerosis	1.1e-06	9.9e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—atherosclerosis	1.09e-06	9.82e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	1.09e-06	9.81e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—atherosclerosis	1.09e-06	9.81e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGT—atherosclerosis	1.08e-06	9.78e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	1.08e-06	9.74e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—atherosclerosis	1.08e-06	9.73e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK3—atherosclerosis	1.08e-06	9.73e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAV1—atherosclerosis	1.08e-06	9.73e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—atherosclerosis	1.08e-06	9.71e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOA1—atherosclerosis	1.07e-06	9.7e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.07e-06	9.7e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—atherosclerosis	1.06e-06	9.61e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—atherosclerosis	1.06e-06	9.58e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—atherosclerosis	1.06e-06	9.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOB—atherosclerosis	1.06e-06	9.56e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARA—atherosclerosis	1.05e-06	9.51e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—atherosclerosis	1.05e-06	9.51e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAV1—atherosclerosis	1.05e-06	9.49e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOA1—atherosclerosis	1.05e-06	9.47e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—atherosclerosis	1.05e-06	9.44e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARA—atherosclerosis	1.04e-06	9.43e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	1.04e-06	9.41e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—atherosclerosis	1.04e-06	9.39e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—atherosclerosis	1.04e-06	9.37e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.03e-06	9.3e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	1.03e-06	9.28e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—atherosclerosis	1.03e-06	9.27e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—atherosclerosis	1.02e-06	9.25e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGT—atherosclerosis	1.02e-06	9.21e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—atherosclerosis	1.02e-06	9.17e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—atherosclerosis	1.02e-06	9.17e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGT—atherosclerosis	1.01e-06	9.13e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—atherosclerosis	1.01e-06	9.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—atherosclerosis	1.01e-06	9.08e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—atherosclerosis	1e-06	9.06e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—atherosclerosis	1e-06	9.05e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—atherosclerosis	1e-06	9.03e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	9.97e-07	9e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCA1—atherosclerosis	9.94e-07	8.97e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—atherosclerosis	9.91e-07	8.95e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAV1—atherosclerosis	9.91e-07	8.94e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOA1—atherosclerosis	9.88e-07	8.92e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—atherosclerosis	9.86e-07	8.9e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—atherosclerosis	9.86e-07	8.9e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAV1—atherosclerosis	9.82e-07	8.87e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—atherosclerosis	9.81e-07	8.86e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOA1—atherosclerosis	9.8e-07	8.85e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—atherosclerosis	9.76e-07	8.81e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	9.66e-07	8.72e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—atherosclerosis	9.63e-07	8.7e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK3—atherosclerosis	9.61e-07	8.67e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CD36—atherosclerosis	9.6e-07	8.67e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—atherosclerosis	9.58e-07	8.65e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—atherosclerosis	9.54e-07	8.61e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	9.49e-07	8.57e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—atherosclerosis	9.47e-07	8.55e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	9.47e-07	8.55e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—atherosclerosis	9.45e-07	8.54e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—atherosclerosis	9.36e-07	8.46e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—atherosclerosis	9.32e-07	8.42e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—atherosclerosis	9.29e-07	8.39e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—atherosclerosis	9.25e-07	8.35e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—atherosclerosis	9.24e-07	8.34e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—atherosclerosis	9.24e-07	8.34e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—atherosclerosis	9.24e-07	8.34e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—atherosclerosis	9.12e-07	8.24e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—atherosclerosis	9.1e-07	8.22e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—atherosclerosis	9.06e-07	8.18e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—atherosclerosis	9.02e-07	8.15e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—atherosclerosis	8.95e-07	8.08e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARA—atherosclerosis	8.93e-07	8.06e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—atherosclerosis	8.77e-07	7.92e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	8.77e-07	7.91e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—atherosclerosis	8.75e-07	7.9e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—atherosclerosis	8.71e-07	7.86e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—atherosclerosis	8.68e-07	7.84e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGT—atherosclerosis	8.64e-07	7.81e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—atherosclerosis	8.63e-07	7.8e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—atherosclerosis	8.54e-07	7.71e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—atherosclerosis	8.53e-07	7.7e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—atherosclerosis	8.52e-07	7.7e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—atherosclerosis	8.52e-07	7.7e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—atherosclerosis	8.51e-07	7.69e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—atherosclerosis	8.47e-07	7.65e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—atherosclerosis	8.47e-07	7.65e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAV1—atherosclerosis	8.39e-07	7.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOA1—atherosclerosis	8.37e-07	7.56e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—atherosclerosis	8.35e-07	7.53e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—atherosclerosis	8.31e-07	7.5e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	8.29e-07	7.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOB—atherosclerosis	8.17e-07	7.37e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—atherosclerosis	8.14e-07	7.35e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—atherosclerosis	8.09e-07	7.3e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—atherosclerosis	8.07e-07	7.29e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	8.05e-07	7.26e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—atherosclerosis	7.97e-07	7.19e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—atherosclerosis	7.97e-07	7.19e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—atherosclerosis	7.95e-07	7.18e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—atherosclerosis	7.95e-07	7.17e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—atherosclerosis	7.88e-07	7.11e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—atherosclerosis	7.83e-07	7.07e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—atherosclerosis	7.8e-07	7.04e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—atherosclerosis	7.76e-07	7.01e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—atherosclerosis	7.64e-07	6.9e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—atherosclerosis	7.61e-07	6.87e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—atherosclerosis	7.51e-07	6.78e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—atherosclerosis	7.49e-07	6.76e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—atherosclerosis	7.45e-07	6.73e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—atherosclerosis	7.43e-07	6.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CD36—atherosclerosis	7.41e-07	6.69e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—atherosclerosis	7.38e-07	6.66e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—atherosclerosis	7.27e-07	6.56e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—atherosclerosis	7.27e-07	6.56e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—atherosclerosis	7.24e-07	6.53e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—atherosclerosis	7.02e-07	6.34e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—atherosclerosis	7.02e-07	6.34e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—atherosclerosis	6.93e-07	6.26e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARA—atherosclerosis	6.89e-07	6.22e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—atherosclerosis	6.85e-07	6.19e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—atherosclerosis	6.79e-07	6.13e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—atherosclerosis	6.76e-07	6.1e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—atherosclerosis	6.7e-07	6.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGT—atherosclerosis	6.67e-07	6.02e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—atherosclerosis	6.63e-07	5.99e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—atherosclerosis	6.54e-07	5.9e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—atherosclerosis	6.48e-07	5.85e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAV1—atherosclerosis	6.48e-07	5.85e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOA1—atherosclerosis	6.46e-07	5.83e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—atherosclerosis	6.35e-07	5.73e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—atherosclerosis	6.06e-07	5.47e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	5.9e-07	5.33e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—atherosclerosis	5.8e-07	5.24e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—atherosclerosis	5.69e-07	5.14e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—atherosclerosis	5.59e-07	5.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—atherosclerosis	5.58e-07	5.04e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—atherosclerosis	5.12e-07	4.62e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—atherosclerosis	4.95e-07	4.47e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—atherosclerosis	4.9e-07	4.42e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—atherosclerosis	4.84e-07	4.37e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—atherosclerosis	4.48e-07	4.04e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—atherosclerosis	4.19e-07	3.79e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—atherosclerosis	3.74e-07	3.38e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—atherosclerosis	3.65e-07	3.3e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—atherosclerosis	3.44e-07	3.11e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—atherosclerosis	3.41e-07	3.08e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—atherosclerosis	2.92e-07	2.63e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—atherosclerosis	2.25e-07	2.03e-06	CbGpPWpGaD
